COR Therapeutics
portfoliocompanies
company snapshot
COR was funded to develop and commercialize innovative pharmaceutical products for the treatment and prevention of severe cardiovascular diseases, such as unstable angina, acute ischemic coronary syndrome and stroke. COR went public in 1991 and was acquired by Millennium in 2001.